ALDX

Aldeyra Therapeutics (ALDX)

Aldeyra Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ALDX

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/08	20 : 00	Business Wire	Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/04/25	20 : 00	Business Wire	Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/04/18	20 : 00	Business Wire	Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/03/28	20 : 00	Business Wire	Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/03/08	06 : 54	Edgar (US Regulatory)	Form S-3 - Registration statement under Securities Act of 1933	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/03/08	06 : 48	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/03/08	06 : 40	Edgar (US Regulatory)	Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/03/08	06 : 06	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/02/06	21 : 00	Business Wire	Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/01/30	07 : 25	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/01/04	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2024/01/04	21 : 00	Business Wire	Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/12/22	06 : 06	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/12/19	21 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/12/19	21 : 00	Business Wire	Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/12/19	06 : 01	Business Wire	Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/28	21 : 16	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/28	06 : 07	Business Wire	Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Dry Eye Disease	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/04	05 : 43	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/04	05 : 08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/01	20 : 09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/11/01	20 : 05	Business Wire	Aldeyra Therapeutics Enters into Exclusive Option Agreement with AbbVie for License to Develop and Commercialize Reproxalap	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/10/16	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/09/27	18 : 45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/09/26	18 : 45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/09/19	18 : 45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/09/12	18 : 45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/09/12	06 : 42	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/08/29	18 : 45	PR Newswire (US)	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Aldeyra Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 29, 2023 - (NASDAQ: ALDX)	NASDAQ:ALDX	Aldeyra Therapeutics Inc
2023/08/25	05 : 13	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ALDX	Aldeyra Therapeutics Inc